Company profile: Sensus Healthcare
1.1 - Company Overview
Company description
- Provider of non-melanoma skin cancer and keloid treatment solutions via SRT-100 Vision, SRT-100+, and SRT-100 devices delivering non-invasive, low-dose Superficial Radiotherapy; includes high-frequency ultrasound imaging and ease of use in outpatient settings. Offers post-surgical keloid radiotherapy to prevent regrowth and a non-surgical alternative to Mohs surgery with a high cure rate.
Products and services
- SRT-100: Delivers non-invasive, low-dose Superficial Radiotherapy for basal cell carcinoma, squamous cell carcinoma, and keloids, eliminating anesthesia and minimizing scarring
- SRT-100+: Utilizes Superficial Radiotherapy to treat non-melanoma skin cancer and keloids, featuring an outpatient-optimized design engineered for ease of use in outpatient settings
- SRT-100 Vision: A compact device delivering non-surgical treatment of non-melanoma skin cancer and keloids, integrating high-frequency ultrasound imaging for lesion visualization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sensus Healthcare
Angiex
HQ: United States
Website
- Description: Provider of vascular-targeted biotherapeutics, developing TM4SF1-directed antibody-drug conjugates for solid tumors, including AGX101, an antibody–microtubule inhibitor conjugate entering Phase 1 to target tumor cells and tumor vascular endothelium; a Nuclear Delivery Platform with antibodies, site-specific conjugation, and linkers for nucleus/cytosol delivery; and a preclinical ND-ADC pipeline using small molecule and protein degrader payloads.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angiex company profile →
IN8bio
HQ: United States
Website
- Description: Provider of gamma-delta T cell immunotherapies for cancer, developing off-the-shelf and genetically modified approaches via its DeltEx platform. Pipeline includes INB-400 (Phase 2) for newly diagnosed glioblastoma using chemotherapy-resistant cells; INB-200 (Phase 1) for newly diagnosed glioblastoma; INB-100 (Phase 1) for leukemia patients undergoing hematopoietic bone marrow transplant; and DeltEx DRI for combination with chemotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IN8bio company profile →
Ernexa
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ernexa company profile →
CytomX Therapeutics
HQ: United States
Website
- Description: Provider of proteolytically activated Probody therapeutics designed to activate only in cancer via tumor-specific proteases, minimizing activity in healthy tissue. Pipeline includes CX-904, a T-cell-engaging bispecific Probody targeting EGFR and CD3 in Phase 1 for advanced solid tumors; CX-2051, a conditionally activated EpCAM-targeting antibody-drug conjugate; and CX-801, an interferon alpha-2b Probody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytomX Therapeutics company profile →
Boundless Bio
HQ: United States
Website
- Description: Provider of precision oncology therapeutics and diagnostics targeting extrachromosomal DNA (ecDNA) in aggressive cancers, including BBI-355 (oral CHK1 inhibitor for ecDNA-enabled oncogene amplified cells), BBI-825 (oral RNR inhibitor disrupting ecDNA assembly and repair), the Spyglass platform to identify and validate druggable targets in ecDNA-cancer cells, and ECHO to detect ecDNA from routine clinical next-generation sequencing data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boundless Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sensus Healthcare
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sensus Healthcare
2.2 - Growth funds investing in similar companies to Sensus Healthcare
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sensus Healthcare
4.2 - Public trading comparable groups for Sensus Healthcare
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →